Zeit | Aktuelle Nachrichten | ||
---|---|---|---|
13.12. | Dietmar Berger is Gilead's new CMO; Padlock investors sue Bristol Myers | ||
13.12. | AbbVie to acquire Roche spinout Nimble in immune drug deal | ||
12.12. | Editas to lay off staff after search for sickle cell partner comes up empty | ||
12.12. | FDA flags additional injury risk for Intercept's liver drug | ||
12.12. | 'Research that's desperately needed': White House conference spotlights women's health | ||
12.12. | Keros shares collapse on 'unanticipated' setback for lung disease drug | ||
11.12. | GLP-1 drug compounding is in limbo. Will the FDA draw out its decision? | ||
11.12. | With new data, Lilly sets pace for next wave of breast cancer drugs | ||
11.12. | Q32 Bio battered by study failure of immune drug | ||
11.12. | BenevolentAI restructures; Lilly preps $15B buyback program | ||
11.12. | Chroma, Nvelop merge to marry genetic medicine 'cargo' to delivery | ||
10.12. | ASH24: Leukemia drug sequencing, sickle cell questions and a new kind of CAR-T | ||
10.12. | UniQure shares soar on chance of speedy approval for Huntington's therapy | ||
10.12. | NewAmsterdam drug shows 'unexpected' signs of protecting the heart in latest study | ||
09.12. | ASH24: Darzalex in smoldering myeloma, Merck's ADC data and Novo's sickle cell drug | ||
09.12. | Gene therapy uptake in sickle cell stays slow, despite patient interest | ||
09.12. | Dimension gets $500M to bankroll biotech's convergence with tech | ||
09.12. | Endometriosis drug research, long underfunded, confronts familiar problems in women's health | ||
09.12. | What's behind pharma's growth boost? | ||
09.12. | Why bioscience and healthcare innovators are looking to Phoenix | ||
09.12. | Clinical services organizations are critical to the future of pharma in the APAC market | ||
06.12. | With conflicts of interest in focus, Trump's pick to run FDA could face scrutiny of his own industry ties | ||
06.12. | Lilly adds to obesity drug production push with $3B investment | ||
06.12. | AstraZeneca, Daiichi build cancer drug case; Amgen invests $1B | ||
05.12. | Atlas doubles down on 'disciplined' biotech investing with latest fundraise |